For months, the struggling New Jersey- based pharmaceutical conglomerate has been struggling, and the numbers they've been producing have only made their financial woes more eviden...
The U.K.'s National Institute for Health and Clinical Excellence (NICE) this weekend issued a draft guidance stating that it does not recommend omalizumab, an...
The U.S. Food and Drug Administration this week approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to...
New trials show that a cancer drug can be an effective treatment for multiple sclerosis (MS) by 'rebooting' patients' immune systems. The results of two phase III clinical trials...